Roche-HIV.com
 
  Home | Disclaimer | Sitemap | Glossary | Library cart | Useful links | Keep me informed | Roche worldwide | Contact webmaster  
  
   Search this site
  Roche in HIV
  News and features
  Press releases
  Animations
  What's new!
  Healthcare professionals

 
  FUZEON PRESS BRIEFING
Posted: 02-Jul-03

 

Please find below a media alert announcing an upcoming news release and press briefing for FUZEON � a revolution in HIV care.  If you have any queries or would like to attend the event then please contact Alexander Watson at Ketchum on Tel: +44 (0) 7712 675 990 / alexander.watson@ketchum.com.

 

MEDIA ALERT

FUZEON � A Revolution in HIV Care - This Changes Everything

No other HIV drug can do what FUZEON does for pre-treated patients

Date:                Tuesday 15 July

Time:               12:15-13:15 CET

Venue:             Room 243, Second Floor, Palais des Congr�s de Paris

 

A FUZEON press briefing at the upcoming International AIDS Society conference (IAS) in Paris will be taking place on Tuesday 15 July.  The event will give you the exclusive opportunity to hear the latest FUZEON news.  There is no other drug like FUZEON, which is the first in a new class of HIV drugs called �Fusion Inhibitors�. FUZEON works in a completely new way to combat the growing problem of HIV resistance in the developed world.

Hear from some of the world�s leading HIV investigators, including both the co-discoverer of HIV and the co-discoverer of FUZEON.

 

AGENDA

Welcome and Introduction

 

 

Prof Robert Gallo

Co-discoverer of HIV retrovirus and

Director of the Institute of Human Virology, University of Maryland Biotechnology Institute

 

The 20th Anniversary of HIV and a New Era in HIV Therapy

Prof Robert Gallo

 

 

FUZEON � A Revolution in HIV Care

 

Dr Dani Bolognesi

Chief Executive Officer and Chief Scientific Officer, Trimeris

 

Remarkable Results � Data Review

Combined TORO 1 & 2 � 24 Week Results

 

Combined TORO 1 & 2 � 48 Week Results

(Accepted as a latebreaker)

 

Prof David Cooper

Professor of Medicine,

University of New South Wales

and Director of the National Centre in HIV Epidemiology and Clinical Research (NCHECR),

Sydney, Australia

 

What FUZEON Means to My Patients

 

 

 

Dr Calvin Cohen

Research Director, Community Research Initiative of New England and Harvard Vanguard Medical Associates

 

Roche�s Commitment to HIV

 

 

Dr David Reddy

HIV Franchise Leader,

Roche

 

Questions to Panel

 

Speaker panel to include:

Dr Miklos Salgo

Opportunity for One to One Interviews

 

 

 

If you have any queries or would like more details about the event then please contact Alexander Watson at Ketchum on Tel: +44 (0) 7712 675 990

 

 


Back Print
Home | Disclaimer | Sitemap | Glossary | Library cart | Useful links | Keep me informed | Roche worldwide
All information contained in this website is generated and maintained by F. Hoffmann-La Roche, Ltd, Basel, Switzerland. This site is intended for use by physicians only. This site is not intended for residents of the United States of America.
Copyright 2006 F. Hoffmann La Roche Ltd.
Contact webmaster